Mednet Logo
HomeGynecologic OncologyQuestion

In patients with recurrent MSI-H endometrial cancer on immunotherapy with pembrolizumab, when do you discontinue therapy?

1 Answers
Mednet Member
Mednet Member
Gynecologic Oncology · University of Alabama at Birmingham

If they have no evidence of disease on their scan, I stop at 2 years.

Register or Sign In to see full answer

In patients with recurrent MSI-H endometrial cancer on immunotherapy with pembrolizumab, when do you discontinue therapy? | Mednet